MX2022006535A - Métodos para tratar síntomas de comportamiento y psicológicos en pacientes con demencia. - Google Patents
Métodos para tratar síntomas de comportamiento y psicológicos en pacientes con demencia.Info
- Publication number
- MX2022006535A MX2022006535A MX2022006535A MX2022006535A MX2022006535A MX 2022006535 A MX2022006535 A MX 2022006535A MX 2022006535 A MX2022006535 A MX 2022006535A MX 2022006535 A MX2022006535 A MX 2022006535A MX 2022006535 A MX2022006535 A MX 2022006535A
- Authority
- MX
- Mexico
- Prior art keywords
- psychological symptoms
- treating behavioral
- dementia patients
- sub
- receptor antagonist
- Prior art date
Links
- 206010012289 Dementia Diseases 0.000 title abstract 2
- 230000003542 behavioural effect Effects 0.000 title abstract 2
- 208000024891 symptom Diseases 0.000 title abstract 2
- HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- ADEBPBSSDYVVLD-UHFFFAOYSA-N donepezil Chemical compound O=C1C=2C=C(OC)C(OC)=CC=2CC1CC(CC1)CCN1CC1=CC=CC=C1 ADEBPBSSDYVVLD-UHFFFAOYSA-N 0.000 abstract 2
- 239000002464 receptor antagonist Substances 0.000 abstract 2
- 229940044551 receptor antagonist Drugs 0.000 abstract 2
- 229940100578 Acetylcholinesterase inhibitor Drugs 0.000 abstract 1
- 239000000544 cholinesterase inhibitor Substances 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 229960003530 donepezil Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- GWCYPEHWIZXYFZ-UHFFFAOYSA-N masupirdine Chemical compound C12=CC(OC)=CC=C2N(S(=O)(=O)C=2C(=CC=CC=2)Br)C=C1CN1CCN(C)CC1 GWCYPEHWIZXYFZ-UHFFFAOYSA-N 0.000 abstract 1
- 229940121461 masupirdine Drugs 0.000 abstract 1
- BUGYDGFZZOZRHP-UHFFFAOYSA-N memantine Chemical compound C1C(C2)CC3(C)CC1(C)CC2(N)C3 BUGYDGFZZOZRHP-UHFFFAOYSA-N 0.000 abstract 1
- 229960004640 memantine Drugs 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
La presente invención proporciona un método para tratar síntomas de comportamiento y psicológicos en paciente con demencia que comprende administrar una dosis efectiva de antagonista receptor de 5-HT6 puro, masupiridina o una sal farmacéuticamente aceptable de los mismos ya sea solos o en combinación con inhibidor de acetilcolinesterasa tal como donepezil y antagonista receptor de NMDA (N-Metil-D-aspartato), memantina; la presente invención además proporciona uso de dicho compuesto en la fabricación de un medicamento y composiciones farmacéuticas que comprenden dichos compuestos hechos para el tratamiento de los trastornos aquí descritos.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN201941049517 | 2019-12-02 | ||
| IN201941049516 | 2019-12-02 | ||
| PCT/IB2020/061383 WO2021111330A1 (en) | 2019-12-02 | 2020-12-02 | Treating behavioral and psychological symptoms in dementia patients |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022006535A true MX2022006535A (es) | 2022-09-09 |
Family
ID=74003821
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022006535A MX2022006535A (es) | 2019-12-02 | 2020-12-02 | Métodos para tratar síntomas de comportamiento y psicológicos en pacientes con demencia. |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20220409614A1 (es) |
| EP (1) | EP4069232A1 (es) |
| JP (1) | JP7556031B2 (es) |
| KR (1) | KR20220108123A (es) |
| CN (1) | CN114901282B (es) |
| AU (1) | AU2020398082A1 (es) |
| BR (1) | BR112022010493A2 (es) |
| CA (1) | CA3162952C (es) |
| IL (1) | IL293416A (es) |
| MX (1) | MX2022006535A (es) |
| WO (1) | WO2021111330A1 (es) |
| ZA (1) | ZA202206042B (es) |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2310243T3 (es) | 2002-11-28 | 2009-01-01 | Suven Life Sciences Limited | Indoles n-aril-3-sulfonil sustituidos que tienen afinidad por receptores de serotonina, proceso para su preparacion y composicion farmaceutica que los contiene. |
| TW200531680A (en) * | 2004-03-03 | 2005-10-01 | Merz Pharma Gmbh & Co Kgaa | Therapy using 1-aminocyclohexane derivatives for the treatment of behavioral disorders associated with alzheimer's disease |
| CA2837926A1 (en) * | 2011-06-03 | 2012-12-20 | Susan ABUSHAKRA | Scyllo - inositol for the treatment of behavioral and psychiatric disorders |
| US9540321B2 (en) | 2013-12-02 | 2017-01-10 | Suven Life Sciences Limited | Process for large scale production of 1-[(2-bromophenyl)sulfonyl]-5-methoxy-3-[(4-methyl-1-piperazinyl)methyl]-1H-indole dimesylate monohydrate |
| EP3458040B1 (en) * | 2016-05-18 | 2021-01-27 | Suven Life Sciences Limited | Combination of pure 5-ht6 receptor antagonists with nmda receptor antagonist |
| SI3458039T1 (sl) * | 2016-05-18 | 2020-11-30 | Suven Life Sciences Limited, | Trojna kombinacija čistih 5-HT6 receptor antagonistov, inhibitorjev acetilholinesteraze in NMDA receptor antagonistov |
| US11458135B2 (en) * | 2016-05-18 | 2022-10-04 | Suven Life Sciences Limited | Combination of pure 5-HT6 receptor antagonists with acetylcholinesterase inhibitors |
| EA202090127A1 (ru) | 2017-07-03 | 2020-04-15 | Сувен Лайф Сайенсиз Лимитед | Новые применения чистого антагониста 5-htрецептора |
-
2020
- 2020-12-02 WO PCT/IB2020/061383 patent/WO2021111330A1/en active Search and Examination
- 2020-12-02 CA CA3162952A patent/CA3162952C/en active Active
- 2020-12-02 IL IL293416A patent/IL293416A/en unknown
- 2020-12-02 US US17/780,734 patent/US20220409614A1/en active Pending
- 2020-12-02 BR BR112022010493A patent/BR112022010493A2/pt unknown
- 2020-12-02 CN CN202080090893.7A patent/CN114901282B/zh active Active
- 2020-12-02 MX MX2022006535A patent/MX2022006535A/es unknown
- 2020-12-02 KR KR1020227022173A patent/KR20220108123A/ko unknown
- 2020-12-02 JP JP2022532840A patent/JP7556031B2/ja active Active
- 2020-12-02 AU AU2020398082A patent/AU2020398082A1/en active Pending
- 2020-12-02 EP EP20829008.0A patent/EP4069232A1/en active Pending
-
2022
- 2022-05-31 ZA ZA2022/06042A patent/ZA202206042B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP7556031B2 (ja) | 2024-09-25 |
| IL293416A (en) | 2022-07-01 |
| CN114901282B (zh) | 2024-06-25 |
| CN114901282A (zh) | 2022-08-12 |
| WO2021111330A1 (en) | 2021-06-10 |
| BR112022010493A2 (pt) | 2022-09-06 |
| ZA202206042B (en) | 2024-09-25 |
| KR20220108123A (ko) | 2022-08-02 |
| CA3162952C (en) | 2024-06-11 |
| EP4069232A1 (en) | 2022-10-12 |
| CA3162952A1 (en) | 2021-06-10 |
| JP2023506724A (ja) | 2023-02-20 |
| AU2020398082A1 (en) | 2022-06-16 |
| AU2020398082A8 (en) | 2022-07-28 |
| US20220409614A1 (en) | 2022-12-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12015502691A1 (en) | Use of high dose pridopidine for treating huntington's disease | |
| WO2005065069A3 (en) | Pharmaceutical methods, dosing regimes and dosage forms for the treatment of alzheimer's disease | |
| EA202191079A1 (ru) | Способы лечения синдрома ретта с применением фенфлурамина | |
| ZA200500152B (en) | Use of reboxetine for the treatment of hot flashes | |
| RU2010107843A (ru) | Бупропиона гидробромид и его терапевтические применения | |
| WO2006106308A1 (en) | Therapeutic use of nefopam and analogues thereof | |
| JP2018522920A5 (es) | ||
| Chazan et al. | Ketamine for acute and subacute pain in opioid-tolerant patients | |
| JP2016505050A5 (es) | ||
| MX2021003508A (es) | Derivados de 5-azaindazol como antagonistas del receptor de adenosina. | |
| Shukla et al. | Comparative study of tramadol and diclofenac as analgesic for postoperative pain | |
| MX2022006535A (es) | Métodos para tratar síntomas de comportamiento y psicológicos en pacientes con demencia. | |
| WO2007062837A2 (en) | Use of a 5-ht4 agonist for the treatment of irritable bowel syndrome characterized by mixed or alternating bowel habits | |
| MX2024006270A (es) | Nueva composicion farmaceutica oral y regimen de dosificacion para la terapia de enfermedades pulmonares intersticiales fibrosantes progresivas. | |
| MX2022006537A (es) | Métodos para tratar síntomas de comportamiento y psicológicos en pacientes con demencia. | |
| MX2023001014A (es) | Composiciones farmaceuticas que comprenden venglustat. | |
| SE0102887D0 (sv) | New formulation | |
| WO2020013776A3 (en) | Synergistic effect of naproxen and a gastro protective agent for the treatment of pain and inflammation | |
| JP2015515971A5 (es) | ||
| RU2020108631A (ru) | Новая вспомогательная терапия для применения в способе лечения рака простаты | |
| MX2022002038A (es) | Composicion farmaceutica para el tratamiento del insomnio. | |
| US20220378769A1 (en) | Use of Glutamate 2B Receptor Antagonists and Sigma Receptor Agonists as Antitussives | |
| SE0102886D0 (sv) | New formulation | |
| MX2022007304A (es) | Uso de lemborexant para tratamiento del insomnio. | |
| SE0102888D0 (sv) | New formulation |